OncoMed Pharmaceuticals — Merger or Acquisition (February 2019)
57 slides from OncoMed Pharmaceuticals's merger presentation, Feb 11, 2019
Slide 1: Combination of Mereo and OncoMed
Filed by OncoMed Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: OncoMed Pharmaceuticals, Inc. (Commission File No.: 001-35993) February 2019 Combination of Mereo AND ONCOM
Slide 2: Disclaimer
Disclaimer Mereo BioPharma Group plc No Offer or Solicitation This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jur
Slide 3: Forward Looking Statements
FORWARD LOOKING STATEMENTS Mereo BioPharma Group plc Forward-Looking Statements This communication contains “forward-looking statements”. All statements other than statements of historical fact contained in this report are forward-looking statements within the meaning of Section 27A of the United St
Slide 4: Key Transaction Terms
Key Transaction TERMS Upfront Stock Consideration Issuance of new Mereo shares (in the form of newly registered ADRs) to OncoMed shareholders Ownership split on completion 75% Mereo / 25% OncoMed shareholders(1) Consideration has an initial value of $54 million(2) and represents an 86% premium to On
Slide 5: Strategic Rationale for the Combination
Strategic Rationale for the Combination Three phase 2 readouts in core orphan products in 2019 (Mereo’s BPS-804 and MPH-966) Potential partnerships of Mereo’s BCT-197 and BGS-649 programs Potential partnership of OncoMed’s navicixizumab Ongoing Celgene collaboration with an option to license OncoMed
Slide 6: Management & Governance
Dr. Peter Fellner Chairman Richard Jones Executive Director CFO Management & Governance John Richard Head of Corporate Development Richard Jones Chief Financial Officer Dr. Denise Scots-Knight Chief Executive Officer Wills Hughes-Wilson Head of Patient Access & Commercial Planning Charles Sermon Gen
Slide 7: Update on the transaction
Update on the transaction Draft Registration Statement on Form F-4 filed with the SEC for Mereo on January 24 2019 Proxy statement of OncoMed included in Mereo Form F-4 OncoMed shareholder meeting to be scheduled Targeting completion in H1 2019
Slide 8: Overview of the Enlarged Mereo
OVERVIEW OF THE ENLARGED MEREO
Slide 9: Corporate and Commercial Strategy
corporate and commercial strategy Mereo BioPharma Group plc The core strategy of the combined business will continue to focus on Orphan Drugs & Rare Diseases Potential new products Core Rare Disease Strategy Bone/ Musculoskeletal Endocrine Respiratory BPS-804 Setrusumab MPH-966 Alvelestat Potential
Slide 10: Overview of Mereo
Overview of mereo Mereo Overview Clinical stage biopharmaceutical company focused on developing products for rare diseases Headquartered in London, UK Successfully completed two Phase 2 studies and a Phase 2b and Phase 2 underway Extensive experience in clinical development, manufacturing, corporate
Slide 11: Overview of OncoMed
Overview of Oncomed OncoMed Overview Clinical stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics Headquartered in Redwood City, California Currently has three therapeutic candidates in clinical development (Phase 1/1b) Extensive experience in adminis
Slide 12: Mereo Upcoming Key Milestones
2019 2020 2021 BPS-804 MPH-966 Partnering BCT-197 BGS-649 NAVI ANTI-TIGIT Additional Rare Disease Products Mereo Upcoming key milestones Pediatric Pivotal 12 month fracture Partnering (regulatory) New product opportunities 6mAdult HRPqCT data 12m 12m Phase 2 POC Study
Slide 13: PPP
PPP SN Mereo BioPharma ~._ ae
Slide 14: Merger Deal Metrics
Merger deal metrics Mereo Oncomed Base (at close) Inc TIGIT CVR Shares in issue 71.2 m 38.6m 95.0 110.2m Price per share (1) £ 1.805 $ 0.75 New shares issued New ADR’s issued (5 for 1) 4.7m (1) 7.8m (3) Equity value $54m (2) $ 70.4m (2) Value per share $1.40 (2) $ 2.30 (2) Premium (to current) (2) 8
Slide 15: Selected Proforma Consolidated Statement of Operations
Selected Proforma consolidated statement of operations (1) for the year ended December 31, 2017 £’m Mereo Oncomed Proforma adjustments Proforma consolidated Collaboration and other revenue - 29.6 - 29.6 Research and development expenses (34.6) (46.4) (2.9) (83.9) Restructuring charges - (2.0) 2.0 -
Slide 16: Selected Proforma Consolidated Balance Sheet
Selected Proforma consolidated Balance sheet(1) as of June 30, 2018 £’m Mereo Oncomed Proforma adjustments Proforma consolidated Property, plant & equipment 0.2 1.9 (0.4) 1.6 Intangible assets 32.7 - 14.4 47.1 Other assets - 1.4 - 1.4 Total non-current assets 32.8 3.3 14.0 50.1 Short-term investment
Slide 17: Combined Group Cash Runway Extended into 2020
Combined group Cash runway extended into 2020 Key go forward funding priorities Funding commitment ended in 2018 Trials ended/ending BCT-197 Phase 2: Completed BGS-649 Phase 2b: completes this year NAVI Phase 1b Etigilimab (anti-TIGIT) Phase 1a GITRL-Fc Trimer Key ongoing studies BPS-804 Adult Phase
Slide 18: Improving Outcomes for Patients in Rare Diseases
Denise Scots-Knight – CEO Richard Jones – CFO Alastair Mackinnon - CMO February 2019 improving outcomes for Patients IN RARE DISEASES
Slide 19: BPS-804 Setrusumab
BPS-804 setrusumab (Acquired from Novartis in 2015)
Slide 20: Osteogenesis Imperfecta, a severe genetic bone disease
Osteogenesis Imperfecta a severe genetic bone disease Mereo BioPharma Group plc
Slide 21: Osteogenesis Imperfecta (OI)
Osteogenesis Imperfecta (OI) An orphan genetic chronic bone disorder characterised by fragile bones that break easily ̴ 6.2 OI cases per 100,000 population in the US 1 ̴ 10 OI cases per 100,000 population in the EU 2 Prevalence: 85% - 90% linked to a gene mutation that produces abnormal type 1 colla
Slide 22: OI Treatment: Drugs Used
OI Treatment: Drugs Used – noNE FDA or EMA approved FOR OI Bisphosphonates Alendronate, risedronate, pamidronate, zoledronate, etc. Approved for treatment of adult osteoporosis Synthetic analogues of pyrophosphate Inhibit bone resorption Can be given orally or intravenously, depending on compound PT
Slide 23: BPS-804 Adult Phase 2B Study
BPS-804 Adult Phase 2B Study Completed enrolment: Trial arms: Study duration: 112 OI Patients Types I, III and IV 6 months open label data 1H 2019 with 12 months H2 2019 Top line data from three blinded arms by the end of 2019 Three different monthly dosing regimens of BPS-804 Open label arm at top
Slide 24: BPS-804 Pediatric Phase 3 Study
BPS-804 – PEDIATRIC Phase 3 study Planned enrolment: 24 patients 5-18 years Total Study duration ~160 Severe OI Patients Types I, III and IV Initiation in 2019 first in EU and Canada Patients on bisphosphonate therapy One month dose finding – 3 doses versus placebo Additional 128 patients Randomised
Slide 25: Brittle Mouse Model Treatment with BPS-804
Brittle Mouse model – treatment with bps-804 Mature Brtl control Mature Brtl treated Mature WT Control Mature WT Treated Mereo Biopharma Group plc
Slide 26: The OFELY Study and HRpQCT
The OFLEY STUDY and HRpQCT Bone Microarchitecture Assessed by HR-pQCT as Predictor of Fracture Risk in Postmenopausal Women Sornay-Rendu et al JBMR March 09 2017 Prospective study investigating the prediction of fracture (Fx) by bone microarchitecture assessed by HRpQCT in postmenopausal women HRpQC
Slide 27: HRpQCT Scans of Patients with OI and Controls
HRpQCT scans of patients with OI and controls Mereo Biopharma Group plc
Slide 28: BPS-804 Regulatory Update
BPS-804 regulatory Update Orphan drug status EU and US PIP agreed with EMA Admitted to the Adaptive Pathway and PRIME in the EU Ongoing interactive dialogue with EMA and HTA’s Real world evidence/registries Plan to engage with the FDA on extending the pediatric Phase 3 trial to sites in the United S
Slide 29: MPH-966 Alvelestat
MPH-966 ALVELESTAT (ACQUIRED FROM ASTRA ZENECA IN 2017)
Slide 30: Alpha-1 Antitrypsin Deficiency (AATD)
Alpha-1 antitrypsin deficiency (AATD) An orphan genetic disorder that results in pulmonary disease North America ~50,000 Europe ~60,000 Estimated prevalence of target patients (PiZZ and Nulls) Symptoms: Age 20-50 - wheeze and reduced exercise tolerance PiZZ and Null adults develop early onset emphys
Slide 31: Restoring the Balance in Alpha-1 Lung Disease with Alvelestat
Restoring the Balance in Alpha-1 Lung Disease with neutrophil elastase inhibitor - alvelestat Elastase Anti-Elastase Alpha-1 antitrypsin Alvelestat
Slide 32: CT Images of Alpha-1 Antitrypsin Deficient Lung
CT Images showing the lung of an alpha-1 antitrypsin deficient patient 31 Normal lung AATD lung Mereo Biopharma Group plc
Slide 33: MPH-966 Relevant Clinical Studies To Date
MPH-966– relevant clinical studies to-date Cystic Fibrosis Total of 56 patients in one study 27 patients treated for 4 weeks with 60mg BD Statistically significant reduction in the biomarker urine desmosine Bronchiectasis Total of 38 patients in one study 22 patients treated for 4 weeks with 60mg BD
Slide 34: MPH-966 Proof of Concept Phase 2 Study
MPH-966 – Proof of Concept Phase 2 Study Three-arm study with two different dosing arms versus placebo Planned enrolment- 165 patients completed Treatment duration- 12 weeks FPI in November 2018 Primary Endpoint Desmosine - biomarker shown to have correlation with lung density by CT scan1 Proposed P
Slide 35: BCT-197 Acumapimod
BCT-197 ACUMAPIMOD (ACQUIRED FROM NOVARTIS IN 2015)
Slide 36: Acute Exacerbations of COPD (AECOPD)
Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) 16m COPD cases diagnosed in the US1 13m COPD cases estimated in the EU2 Prevalence: >1.5m Hospital visits per year3 COPD includes chronic bronchitis, emphysema and some forms of bronchiectasis Symptoms AECOPD - patients with COPD
Slide 37: BCT-197 Met Primary Endpoint in Phase 2 Trial
Primary endpoint (change in FEV1 from baseline to day 7 within the treatment group) Primary endpoint met on an ITT basis for both high and low dose regimens (p= 0.012, p ≤ 0.001) versus no significant change from baseline (p=0.102) for Standard of Care plus placebo Positive clinical and health econo
Slide 38: BGS-649 Leflutrozole
BGS-649 LEFLUTROZOLE (ACQUIRED FROM NOVARTIS IN 2015)
Slide 39: Hypogonadotropic Hypogonadism in Obese Men
Hypogonadotropic Hypogonadism (HH) in obese men A highly prevalent clinical syndrome that results from inadequate levels of testosterone ̴ 35.5% Adult males in the US are obese 1 ̴ 21.9% Adult males in the EU are obese 1 Prevalence: ̴ 15.8% HH prevalence in obese men 2 12 million* obese men with HH
Slide 40: BGS-649 Met Primary Endpoint in Phase 2b Trial
BGS-649 met the primary end point in the Phase 2b trial Total of 271 patients PRIMARY ENDPOINT: normalisation of testosterone @ 24 wk in >75% subjects Met at all three doses p<0.001 versus placebo No patient >1500 ng/dl at any time point, in the treatment groups SECONDARY ENDPOINT: normalisation of
Slide 41: BGS-649 Met Secondary Endpoints in Phase 2b Trial
BGS-649 met the secondary end points in the phase 2b trial Total of 271 patients LS Mean change from baseline in FSH in ITT population (MMRM) LS Mean change from baseline in LH in ITT population (MMRM) SECONDARY ENDPOINTS Change in fertility hormones (LH and FSH) from baseline at 24 weeks met by all
Slide 42: 1H 2018 Mereo Financial Results
1H 2018 mereo Financial results
Slide 43: Financial Highlights
Financial Highlights Mereo BioPharma Group plc £126 million* R&D spend in 1H 2018 £10.9 million Cash and short term deposits and short term investments at June 30 2018: £36.9 million* £7.1 million Funded through to key clinical milestones *(gross including debt facility) (£3.8m on non-GAAP adjusted
Slide 44: Appendix
appendix
Slide 45: Robust Intellectual Property Portfolio
Robust Intellectual property portfolio 2019 2021 2023 2025 2027 2029 2031 2033 2035 2037 Compound per se – granted in all major territories Compound per se – granted in all major territories BCT-197 MPH-966 BPS-804 Antibody and use – granted in all major territories 1Data & Marketing Exclusivity - E
Slide 46: Transaction Entitlements: Mereo and NVS/AZ
Transaction Mereo Entitlement NVS/AZ Entitlement Licence of product in territory or worldwide Majority percent of licensing income (upfront, milestones and royalties) Share of licensing income (upfront, milestones and royalties) Commercialisation by Mereo (territory or worldwide) Product sales Ascen
Slide 47: Setrusumab: Mechanism of Action
Setrusumab: Mechanism of Action In the absence of sclerostin, Wnt activates Dishevelled through LRP 5/6/Frizzled The intracellular pathways upregulate target gene expression, osteoblast differentiation, proliferation & survival, leading to increased bone formation Sclerostin (secreted by osteocytes)
Slide 48: Alpha Antitrypsin Deficiency Current Treatment
Alpha 1 antitrypsin deficiency current treatment Routine COPD medications Augmentation therapy: Plasma derived alpha 1 anti trypsin Weekly one hour IV infusion Approval based on restoration of A1AT to a threshold level NOT clinical outcome data Cost $150k pa ~9,000 patients treated Surgery – lung vo
Slide 49: RAPID Study: Impact on Desmosine
long term augmentation and short term treatment with AZD-9668 –impact on desmosine RAPID study - 2 years of augmentation in AATD patients Reduced loss of lung density: Total lung capacity (TLC) -1.45g/l/year vs -2.19 g/l/year (P=0.03) Post hoc analysis demonstrated correlation in change in desmosine
Slide 50: BCT-197 Reduced Inflammatory Markers HsCRP and Fibrinogen
BCT-197 resulted in a significant reduction in the inflammatory markers HsCRP and fibrinogen in the first 14 days during the index exacerbation Dose – dependent, statistically significant reductions in key inflammatory markers hsCRP and fibrinogen Suppression of hsCRP maintained through the 26-week
Slide 51: BCT197 Reduced Subsequent Exacerbations in Frequent Exacerbators
BCT197 reduced the Percentage of patients who suffered a subsequent exacerbation in frequent exacerbators Effect on moderate/severe exacerbations best seen in patients with >= 2 exacerbations / year Patient population with highest unmet need Mereo Biopharma Group plc
Slide 52: BGS-649 (HH): HPT Feedback Loop Process
BGS-649 (HH): HPT Feedback loop process
Slide 53: PPP
PPP SN Mereo BioPharma ~._ ae
Slide 54: Summary of Financial Results
Mereo BioPharma Group plc Summary of Financial results For the six months ended June, 30 2018 H1’18 H1’18 £’000 Share based payments £’000 Fx £’000 One off legal costs £’000 H1’2018 Non-GAAP £’000 H1’2017 Non-GAAP £’000 Development costs (10,864) 337 - (10,527) (20,823) Admin expenses (7,102) 1,080
Slide 55: R&D Costs by Segment
R&D costs by segment (£’m) Total R&D costs H1 ‘18 £10.9m (H1’17: £21.4m) Mereo BioPharma Group plc
Slide 56: Total Operating Costs by Segment
Total Operating costs by segment (£’m) Total spend (operating loss) in 2017 £45.3m Mereo BioPharma Group plc
Slide 57: Mereo BioPharma Group plc
Mereo BioPharma Group plc One Cavendish Place London, W1G 0QF UK +44 (0)333 0237 300
OncoMed Pharmaceuticals — Merger or Acquisition (February 2019) on 6ix